Alcon pushes ahead with WaveLight merger
This article was originally published in Clinica
Executive Summary
Alcon's proposed acquisition of Erlangen, Germany-based eye correction laser and diagnostic systems developer WaveLight has cleared another hurdle, just days after receiving antitrust approval from the German authorities. WaveLight's board of directors this week gave the thumbs up to Alcon's "very attractive" offer of E15 ($20.23) per share, and recommended that shareholders tendered their shares to the Fort Worth, Texas company. Alcon had originally agreed to pay E10 per share when it announced the proposed acquisition in mid-July (see Clinica No 1265, p 12), but recently upped its offer by E5 to reflect positive trading activity. The tender offer, which was initiated on August 13, will conclude on September 11.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.